

Title: Dual Src and EGFR Inhibition in Combination with Gemcitabine in Advanced Pancreatic Carcinoma: Phase I Results

Journal Name: Investigational New Drugs

Authors: Dana B. Cardin, MD^{1,2}, Laura W. Goff, MD^{1,2}, *Emily Chan, MD, PhD³, Jennifer G. Whisenant, PhD^{1,2}, G. Dan Ayers, MS^{4,5}, Naoko Takebe, MD, PhD⁶, Lori R. Arlinghaus, PhD⁷, Thomas E. Yankeelov, PhD⁸, Jordan Berlin, MD^{1,2}, Nipun Merchant, MD⁹

¹Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA

²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

³Amgen Inc., Thousand Oaks, CA, USA

⁴Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

⁵Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

⁶Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA

⁷Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA

⁸Institute for Computational and Engineering Sciences, Departments of Biomedical Engineering and Diagnostic Medicine, Livestrong Cancer Institutes, University of Texas, Austin, TX, USA

⁹Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA

Please address correspondence to:

Dana B. Cardin, MD

dana.cardin@vanderbilt.edu

Supplemental Figure 1: CA19-9 levels correlate with changes in tumor size. Moderate and significant positive correlation (Pearson Correlation = 0.65, p=0.023) observed between changes in CA19-9 levels at four weeks and tumor size at eight weeks.

